Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 150

1.

Preventive and therapeutic vaccines against Helicobacter pylori: current status and future challenges.

Ernst PB, Pappo J.

Curr Pharm Des. 2000 Oct;6(15):1557-73. Review.

PMID:
10974152
2.
3.

A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States.

Rupnow MF, Shachter RD, Owens DK, Parsonnet J.

Emerg Infect Dis. 2000 May-Jun;6(3):228-37.

4.

Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori.

Yamaguchi H, Osaki T, Kai M, Taguchi H, Kamiya S.

Infect Immun. 2000 Jun;68(6):3448-54.

5.

Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate.

Keenan J, Oliaro J, Domigan N, Potter H, Aitken G, Allardyce R, Roake J.

Infect Immun. 2000 Jun;68(6):3337-43.

6.

Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy.

Fox JG, Beck P, Dangler CA, Whary MT, Wang TC, Shi HN, Nagler-Anderson C.

Nat Med. 2000 May;6(5):536-42.

PMID:
10802709
7.

The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor.

Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Montecucco C, Rossi F.

J Exp Med. 2000 May 1;191(9):1467-76.

8.
9.

Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta).

Solnick JV, Canfield DR, Hansen LM, Torabian SZ.

Infect Immun. 2000 May;68(5):2560-5.

10.

Interleukin-1 polymorphisms associated with increased risk of gastric cancer.

El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS.

Nature. 2000 Mar 23;404(6776):398-402. Erratum in: Nature 2001 Jul 5;412(6842):99.

PMID:
10746728
11.

Induction and maintenance of immune effector cells in the gastric tissue of mice orally immunized to Helicobacter pylori requires salivary glands.

Shirai Y, Wakatsuki Y, Kusumoto T, Nakata M, Yoshida M, Usui T, Iizuka T, Kita T.

Gastroenterology. 2000 Apr;118(4):749-59.

PMID:
10734026
13.

Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion.

Odenbreit S, Püls J, Sedlmaier B, Gerland E, Fischer W, Haas R.

Science. 2000 Feb 25;287(5457):1497-500.

14.

Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies.

Sutton P, Wilson J, Kosaka T, Wolowczuk I, Lee A.

Immunol Cell Biol. 2000 Feb;78(1):28-30.

15.
16.

Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer.

Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG.

Gastroenterology. 2000 Jan;118(1):36-47.

PMID:
10611152
17.

Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology.

Rupnow MF, Owens DK, Shachter R, Parsonnet J.

Helicobacter. 1999 Dec;4(4):272-80.

PMID:
10597398
18.

A proinflammatory cytokine inhibits p53 tumor suppressor activity.

Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH.

J Exp Med. 1999 Nov 15;190(10):1375-82.

19.

BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma.

Mazzucchelli L, Blaser A, Kappeler A, Schärli P, Laissue JA, Baggiolini M, Uguccioni M.

J Clin Invest. 1999 Nov;104(10):R49-54.

20.

Impaired T-cell regulation of B-cell growth in Helicobacter pylori--related gastric low-grade MALT lymphoma.

D'Elios MM, Amedei A, Manghetti M, Costa F, Baldari CT, Quazi AS, Telford JL, Romagnani S, Del Prete G.

Gastroenterology. 1999 Nov;117(5):1105-12.

PMID:
10535873

Supplemental Content

Support Center